These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21637921)

  • 1. All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma.
    Alloussi SH; Alkassar M; Urbschat S; Graf N; Gärtner B
    Oncol Rep; 2011 Sep; 26(3):645-9. PubMed ID: 21637921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oncolytic reovirus against human breast cancer cells.
    Hata Y; Etoh T; Inomata M; Shiraishi N; Nishizono A; Kitano S
    Oncol Rep; 2008 Jun; 19(6):1395-8. PubMed ID: 18497942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
    Shmulevitz M; Lee PW
    Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reovirus and tumor oncolysis.
    Kim M; Chung YH; Johnston RN
    J Microbiol; 2007 Jun; 45(3):187-92. PubMed ID: 17618222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic viral therapy using reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer.
    Shmulevitz M; Marcato P; Lee PW
    Oncogene; 2005 Nov; 24(52):7720-8. PubMed ID: 16299532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.
    Stoeckel J; Hay JG
    Curr Opin Mol Ther; 2006 Jun; 8(3):249-60. PubMed ID: 16774045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
    Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
    Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures.
    van den Hengel SK; Balvers RK; Dautzenberg IJ; van den Wollenberg DJ; Kloezeman JJ; Lamfers ML; Sillivis-Smit PA; Hoeben RC
    Cancer Gene Ther; 2013 Sep; 20(9):507-13. PubMed ID: 23907517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
    Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
    J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of mantle cell lymphomas to reovirus oncolysis.
    Alain T; Muzik H; Otsuka S; Chan S; Magliocco T; Diaz R; Forsyth PA; Morris D; Bebb G
    Leuk Res; 2010 Jan; 34(1):100-8. PubMed ID: 19651440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
    Kapadia R; Coffey MC
    Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
    Leske H; Haase R; Restle F; Schichor C; Albrecht V; Vizoso Pinto MG; Tonn JC; Baiker A; Thon N
    Anticancer Res; 2012 Apr; 32(4):1137-44. PubMed ID: 22493342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
    Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oncolytic virus therapy for malignant brain tumors].
    Ino Y; Todo T
    Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reovirus - possible therapy of cancer.
    Figova K; Hrabeta J; Eckschlager T
    Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of mammalian reoviruses for use as oncolytic agents.
    Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
    Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reovirus as an oncolytic agent against experimental human malignant gliomas.
    Wilcox ME; Yang W; Senger D; Rewcastle NB; Morris DG; Brasher PM; Shi ZQ; Johnston RN; Nishikawa S; Lee PW; Forsyth PA
    J Natl Cancer Inst; 2001 Jun; 93(12):903-12. PubMed ID: 11416111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of oncolytic reovirus in canine lymphoma cell lines.
    Hwang CC; Umeki S; Igase M; Coffey M; Noguchi S; Okuda M; Mizuno T
    Vet Comp Oncol; 2016 Aug; 14 Suppl 1():61-73. PubMed ID: 25319493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.